Free Trial

Inozyme Pharma (INZY) Competitors

Inozyme Pharma logo
$4.00 0.00 (0.00%)
As of 07/1/2025

INZY vs. ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, AVDL, PHVS, and NRIX

Should you be buying Inozyme Pharma stock or one of its competitors? The main competitors of Inozyme Pharma include Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

Inozyme Pharma vs. Its Competitors

Inozyme Pharma (NASDAQ:INZY) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Enliven Therapeutics' return on equity of -31.84% beat Inozyme Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Inozyme PharmaN/A -159.93% -82.48%
Enliven Therapeutics N/A -31.84%-30.09%

Inozyme Pharma has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Inozyme Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inozyme PharmaN/AN/A-$102.02M-$1.69-2.37
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-10.20

88.3% of Inozyme Pharma shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 12.2% of Inozyme Pharma shares are owned by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Inozyme Pharma presently has a consensus price target of $11.75, indicating a potential upside of 193.75%. Enliven Therapeutics has a consensus price target of $41.20, indicating a potential upside of 110.31%. Given Inozyme Pharma's higher probable upside, research analysts plainly believe Inozyme Pharma is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inozyme Pharma
0 Sell rating(s)
5 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.44
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Enliven Therapeutics had 7 more articles in the media than Inozyme Pharma. MarketBeat recorded 13 mentions for Enliven Therapeutics and 6 mentions for Inozyme Pharma. Enliven Therapeutics' average media sentiment score of 0.69 beat Inozyme Pharma's score of 0.32 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inozyme Pharma
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enliven Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Enliven Therapeutics beats Inozyme Pharma on 9 of the 12 factors compared between the two stocks.

Get Inozyme Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INZY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INZY vs. The Competition

MetricInozyme PharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$258.25M$2.92B$5.53B$9.03B
Dividend YieldN/A2.44%5.24%4.01%
P/E Ratio-2.377.5519.3119.89
Price / SalesN/A284.29424.59117.07
Price / CashN/A41.7026.2128.59
Price / Book4.447.397.925.55
Net Income-$102.02M-$55.04M$3.17B$248.49M
7 Day PerformanceN/A3.01%2.18%5.37%
1 Month Performance0.25%-0.21%1.25%6.63%
1 Year Performance-10.91%4.48%33.90%21.20%

Inozyme Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INZY
Inozyme Pharma
3.382 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750Positive News
Analyst Upgrade
ELVN
Enliven Therapeutics
2.6637 of 5 stars
$20.06
-3.0%
$39.60
+97.4%
-7.8%$1.01BN/A0.0050Analyst Revision
VERV
Verve Therapeutics
3.3393 of 5 stars
$11.23
-0.6%
$14.57
+29.8%
+113.8%$1.01B$32.33M0.00110
NTLA
Intellia Therapeutics
4.7082 of 5 stars
$9.38
-1.9%
$33.37
+255.7%
-52.9%$990.25M$57.88M-1.79600
COLL
Collegium Pharmaceutical
4.2534 of 5 stars
$29.57
-1.2%
$43.75
+48.0%
-5.6%$961.71M$631.45M24.24210News Coverage
Analyst Downgrade
Gap Up
AKBA
Akebia Therapeutics
4.2296 of 5 stars
$3.64
-0.3%
$6.75
+85.4%
+285.3%$958.62M$160.18M-17.33430
SYRE
Spyre Therapeutics
1.3377 of 5 stars
$14.97
-1.6%
$53.40
+256.7%
-37.9%$917.39M$890K0.0073
MLYS
Mineralys Therapeutics
2.1255 of 5 stars
$13.53
-1.3%
$32.25
+138.4%
+16.9%$893.55MN/A0.0028
AVDL
Avadel Pharmaceuticals
2.4185 of 5 stars
$8.85
-3.8%
$18.17
+105.3%
-39.6%$890M$169.12M-32.7870
PHVS
Pharvaris
1.5503 of 5 stars
$17.60
+3.5%
$36.20
+105.7%
+12.7%$888.93MN/A0.0030
NRIX
Nurix Therapeutics
1.5943 of 5 stars
$11.39
-2.1%
$30.18
+164.9%
-34.6%$887.38M$54.55M0.00300Upcoming Earnings
Gap Down

Related Companies and Tools


This page (NASDAQ:INZY) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners